Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News LogicBio Therapeutics Inc. LOGC

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.


Recent & Breaking News (NDAQ:LOGC)

LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference

PR Newswire March 23, 2022

LogicBio Therapeutics to Present at Barclays Global Healthcare Conference

PR Newswire March 8, 2022

LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

PR Newswire March 4, 2022

LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program

PR Newswire February 2, 2022

LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

PR Newswire January 4, 2022

LogicBio Therapeutics Provides Business Updates

PR Newswire December 22, 2021

LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

PR Newswire November 15, 2021

LogicBio Therapeutics to Participate in Upcoming Investor Conferences

PR Newswire November 11, 2021

LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide(TM) Genome Editing Technology

PR Newswire October 21, 2021

LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children

PR Newswire October 18, 2021

LogicBio Therapeutics to Present New GeneRide(TM) Data at the European Society of Gene and Cell Therapy Virtual Congress 2021

PR Newswire October 12, 2021

LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

PR Newswire September 24, 2021

LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PR Newswire September 10, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC

GlobeNewswire February 11, 2020

LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia

GlobeNewswire February 10, 2020

LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones

GlobeNewswire January 10, 2020

LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome

GlobeNewswire January 10, 2020

LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide(TM) Candidates

GlobeNewswire December 17, 2019

LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates

GlobeNewswire November 12, 2019

LogicBio Therapeutics to Present at November Conferences

GlobeNewswire November 7, 2019